Clinical Development In-Vitro Licensing Production 
The Pharma Data
JANUARY 12, 2021
Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Dr. Graham earned an M.D.,
The Pharma Data
APRIL 4, 2022
Chief Medical Officer and Head of Global Product Development, Roche. today announced that the U.S. FDA approval is expected in the second half of this year. 7 Implementing an international differentiated pricing strategy specifically designed to address needs during this pandemic and improve affordability.7
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 31, 2023
C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. It is expected to accelerate the development of CFT8919 in important international markets.
The Pharma Data
MARCH 29, 2022
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 2 subvariant, now the dominant strain in Europe. 1-3 Evusheld was generally well-tolerated in the trial. Christoph D.
Pharmaceutical Technology
AUGUST 26, 2008
It started to emerge in the mid 1990s, incrementally gathering speed as more products were approved in the last ten years,” says Reilly. “The pharmaceutical industry is increasingly embracing large molecule products and concepts.” “Biotechnology has exploded across the industry. .
The Pharma Data
MAY 15, 2023
Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Vabysmo® (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO). Roche’s Chief Medical Officer and Head of Global Product Development. “If In BALATON, vision gains were +16.9
The Pharma Data
DECEMBER 9, 2020
Uniquely positioned in the rapidly evolving local biotech ecosystem in China in addition to an expansive global presence, Overland will strategically partner to jointly develop innovative, novel therapeutics. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.
Expert insights. Personalized for you.
52 
Let's personalize your content